Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: Association with insulin resistance, adiponectin, and polycystic ovary syndrome history

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Wang, Dongyu ^a   Zhu, Wenjing ^a   Li, Jieming ^a   An, Chongyou ^a   Wang, Zilian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; INSULIN; TRIACYLGLYCEROL;

ADULT; BLOOD; CASE CONTROL STUDY; COMPLICATION; DIABETES COMPLICATIONS; FEMALE; GENE EXPRESSION; GENETICS; GESTATIONAL AGE; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY DIABETES MELLITUS;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES, GESTATIONAL; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; GESTATIONAL AGE; HUMANS; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; PREGNANCY; TRIGLYCERIDES;

EID: 84894157731     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081190     Document Type: Article

References (42)

1. Zhu WW, Fan L, Yang HX, Kong LY, Su SP, et al. (2013) Fasting Plasma Glucose at 24-28 Weeks to Screen for Gestational Diabetes Mellitus: New evidence from China. Diabetes Care 36:2038-2040.
2. HAPO Study Cooperative Research Group (2009) Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes 58:453-459.
3. Barnes-Powell LL (2007) Infants of diabetic mothers: the effects of hyperglycemia on the fetus and neonate. Neonatal Netw 26:283-290.
4. Bo S, Valpreda S, Menato G, Bardelli C, Botto C, et al. (2007) Should we consider gestational diabetes a vascular risk factor? Atherosclerosis 194:e72-e79. (Pubitemid 47513087)
5. Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373:1773-1779.
6. Damm P (2009) Future risk of diabetes in mother and child after gestational diabetes mellitus. Int J Gynaecol Obstet 104: S25-S26.
7. Bergmann K, Sypniewska G (2013) Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin Chem Lab Med 51:177-185.
8. Retnakaran R, Hanley AJ, Raif N, Hirning CR, Connelly PW, et al. (2005) Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. Diabetologia 48:993-1001. (Pubitemid 40767994)
9. Lain KY, Daftary AR, Ness RB, Roberts JM (2008) First trimester adipocytokine concentrations and risk of developing gestational diabetes later in pregnancy. Clin Endocrinol (Oxf)69:407-411.
10. Qiu C, Williams MA, Vadachkoria S, Frederick IO, Luthy DA (2004) Increased maternal plasma leptin in early pregnancy and risk of gestational diabetes mellitus. Obstet Gynecol 103:519-525. (Pubitemid 40459068)
11. Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, et al. (2007) Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 50:1033-1037. (Pubitemid 46559248)
12. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC, Huston-Presley L, et al. (2002) TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes 51: 2207-2213. (Pubitemid 34729026)
13. Krzyzanowska K, Zemany L, Krugluger W, Schernthaner GH, Mittermayer F, et al. (2008) Serum concentrations of retinol-binding protein 4 in women with and without gestational diabetes. Diabetologia 51: 1115-1122.
14. Potthoff MJ, Kliewer SA, Mangelsdorf DJ (2012) Endocrine fibroblast growth factors15/19 and 21: from feast to famine. Genes Dev 26: 312-324.
15. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, et al. (2012) Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 7: e38438
16. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603. (Pubitemid 38686202)
17. Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, et al. (2011) Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152:2996-3004.
18. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, et al. (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621-1624
19. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, et al. (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55:2470-2478. (Pubitemid 44871147)
20. Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, et al. (2011) Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 41:390-396.
21. Mráz M, Lacinová Z, Kaválková P, Haluzíková D, Trachta P, et al. (2011) Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-a agonist treatment. Physiol Res 60:627-636.
22. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-1253.
23. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, et al. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71:369-375.
24. Chen C, Cheung BM, Tso AW, Wang Y, Law LS, et al. (2011) High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 34:2113-2115.
25. Bobbert T, Schwarz F, Fischer-Rosinsky A, Pfeiffer AF, Möhlig M, et al. (2013) Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 36:145-149.
26. Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren HJ, et al. (2010) Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 59:33-37.
27. Yang HX (2012) Diagnostic criteria for gestational diabetes mellitus (WS 331- 2011). Chin Med J (Engl) 125:1212-1213.
28. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-47.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419. (Pubitemid 15018832)
30. Tomlinson E, Fu L, John L, Hultgren B, Huang X, et al. (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741-1747. (Pubitemid 34415889)
31. Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, et al. (2010) The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 298:G440-G445.
32. Reiche M, Bachmann A, Lössner U, Blüher M, Stumvoll M, et al. (2010) Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 42:178-181.
33. Gallego-Escuredo JM, Domingo P, Gutiérrez Mdel M, Mateo MG, Cabeza MC, et al. (2012) Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients. J Acquir Immune Defic Syndr 61:527-534.
34. Lundasen T, Gälman C, Angelin B, Rudling M (2006) Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260:530-536. (Pubitemid 44772372)
35. Stejskal D, Karpísek M, Hanulová Z, Stejskal P (2008) Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest 68:501-507.
36. Shin DJ, Osborne TF (2009) FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 284:11110-11120.
37. Chang RJ, Nakamura RM, Judd HL, Kaplan SA (1983) Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57:356-359. (Pubitemid 13032489)
38. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, et al. (2006) A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12: 673-683. (Pubitemid 44605508)
39. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, et al. (2009) Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 15:297-307.
40. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774-781. (Pubitemid 46143178)
41. Dostálová I, Kaválková P, Haluzíková D, Lacinová Z, Mráz M, et al. (2008) Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93:3627-3632.
42. Angelin B, Larsson TE, Rudling M (2012) Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab 16:693-705.